INTENSITY MODULATED RADIATION THERAPY IN THE ADJUVANT TREATMENT OF RESECTED GASTRIC CANCER: A RETROSPECTIVE DOSIMETRIC AND CLINICAL ANALYSIS

The European Society for Medical Oncology guidelines recommend adjuvant chemoradiation for patients with resected gastric cancer who have not undergone an appropriate D2 lymphadenectomy or have involved margins. In this setting, due to the requirement to cover large irradiation volumes and to deliver concomitant systemic therapy, treatment-related toxicities remain a concern. With the goal of assessing safety and feasibility of adjuvant radiotherapy, we collected data of patients with resected gastric cancer, who underwent Intensity Modulated Radiation Therapy to 50.4 Gy, concurrent with fluoropyrimidine based chemotherapy at our institution, between January 2016 and January 2022. In this study, we examined dose distribution to PTV and organs at risk, demonstrating safety and feasibility of this treatment without significant acute or late toxicities.